Ibogaine's primary mechanism—upregulation of GDNF, glial cell line-derived neurotrophic factor—acts directly on the dopaminergic pathways that stimulant addiction damages. The mechanism is relevant to cocaine and methamphetamine use disorder. What it is not, yet, is a treatment with the same evidence base as ibogaine for opioid dependence. The preclinical research is real. The human case series are encouraging. Phase 3 clinical trials for stimulant use disorder specifically have not been completed.
Who cannot proceed applies regardless of which condition is being addressed. Cardiac screening, medication review, and psychiatric assessment are required before any ibogaine ceremony—whether the presenting concern is opioid dependence, stimulant use disorder, PTSD, or depression.
- Active ibogaine experience: 12–24 hours
- Primary mechanism relevant to stimulants: GDNF upregulation in dopaminergic midbrain pathways
- Evidence level: animal models and case series—not yet completed Phase 3 trials for stimulant use disorder specifically
- Unlike opioid dependence: ibogaine does not interrupt acute physical withdrawal from stimulants
- Absolute contraindications apply regardless of condition: cardiac, SSRIs/SNRIs, active psychosis, liver disease, pregnancy
Why the mechanism applies to stimulant addiction
Chronic cocaine and methamphetamine use depletes dopaminergic function in the midbrain. Prolonged stimulant exposure downregulates D2 dopamine receptor density and reduces baseline output from dopamine-producing neurons—the same structures that GDNF supports. This is not incidental. It is the neurobiological substrate of stimulant addiction: a blunted reward system that requires escalating doses to produce the same effect, and that produces dysphoria and anhedonia during abstinence. The National Institute on Drug Abuse has documented these dopaminergic changes extensively in both cocaine and methamphetamine research.
Ibogaine upregulates GDNF expression in the midbrain—in animal models, persistently and at concentrations above normal after the acute experience ends. GDNF is a trophic factor: it supports the survival, repair, and functional recovery of dopaminergic neurons. If ibogaine's GDNF effect in humans is similar to what is observed in rodent models, it addresses the neurobiological substrate of stimulant addiction directly—not by substituting a controlled stimulant or blunting craving pharmacologically, but by attempting to restore the function that chronic stimulant use degraded.
That is the mechanism. It is coherent. It does not prove efficacy in clinical trials for stimulant use disorder, which have not been completed. What it provides is a credible biological rationale for why ibogaine might work for this population—and why researchers are investigating it.
What the preclinical research shows
The animal model evidence is consistent. Ibogaine reduces cocaine self-administration in rodents—a well-replicated finding across independent research groups going back to the early 1990s. Similar findings have been observed for methamphetamine. The effect appears to outlast the acute experience: ibogaine administered in a single session reduces stimulant-seeking behaviour in animal models for periods longer than the drug's direct pharmacological activity.
Human data is more limited. Retrospective studies and case series document reduced cocaine and methamphetamine use following ibogaine treatment—but this research is observational, not controlled. People who seek ibogaine treatment are self-selected; those who complete a full protocol and report reduced use cannot be easily compared to a population that did not receive treatment. Selection bias is real in this literature.
The 2023 Stanford study in Nature Medicine documented 88% reduction in PTSD symptoms, 87% reduction in depression, and 81% reduction in anxiety at one month in 30 special operations veterans. That population had PTSD and traumatic brain injury, not primarily stimulant use disorder. The GDNF mechanism ibogaine engaged is the same mechanism relevant to stimulant addiction—but drawing a direct line from those results to stimulant outcomes would overstate what the data actually show.
Texas committed $50 million USD to ibogaine clinical trials at UTMB, UTHealth Houston, Texas A&M, and Baylor University after the Stanford findings. Stimulant use disorder is within the scope of what those trials are designed to examine. The results are not yet available.
How stimulant addiction differs from opioid dependence
The most documented ibogaine effect in opioid dependence is withdrawal interruption. Ibogaine modulates opioid receptors directly, suppressing acute withdrawal syndrome within hours of administration. This is the effect that drove the first wave of ibogaine addiction research and that the Stanford veterans cohort built upon.
Stimulant use disorder does not produce significant acute physical withdrawal in the same sense. Cocaine and methamphetamine cessation produces psychological withdrawal—dysphoria, anhedonia, fatigue, craving—but not the physiologically dangerous syndrome of opioid withdrawal. There is no acute physical withdrawal state for ibogaine to interrupt.
This changes the clinical picture but not the mechanism. Ibogaine's relevance to stimulant addiction is GDNF-mediated neuroplasticity and the potential restoration of dopaminergic function that chronic stimulant use degraded. The person is not arriving in acute physical crisis. They are arriving with a depleted dopamine system, strong psychological craving, and often a long history of failed attempts through conventional means.
The preparation is also different. Opioid-dependent people—especially fentanyl users—require a supervised medical detox before ibogaine can be safely administered, because fentanyl accumulates in fat tissue and redistributes back into circulation over days after cessation. Stimulant-dependent people do not require that protocol. Abstinence for several days before ceremony is standard practice, but it does not involve the complex medically supervised clearance that fentanyl necessitates. See ibogaine for fentanyl addiction for the specific fentanyl preparation requirements.
Why integration matters more here, not less
For opioid dependence, the dramatic interruption of physical withdrawal is itself a kind of anchor—a concrete, observable demonstration that something has changed. Stimulant-dependent people do not have that anchor. What ibogaine provides is a neuroplasticity window and, for many people, a confrontation with the psychological and biographical material that sustained the problem. The physical condition does not change in the same acute, visible way.
This makes the integration window more critical, not less. The weeks to months following ibogaine ceremony—when noribogaine remains biologically active and the brain is in a state of elevated receptivity to change—are when the work that determines long-term outcomes happens. The pattern practitioners observe most consistently is not the ceremony being insufficient. It is the ceremony being unused. The person left with clarity, reduced craving, and what felt like the beginning of something different. Six weeks later, they were back where they started—or worse, because the contrast between what was possible and what they had returned to was now sharper. This happens when people return immediately to the environment and relationships that produced the problem, without integration support in place.
Integration support is not a bonus offered by some providers and not others. It determines whether the ceremony produces lasting change. For stimulant use disorder in particular, the structural work—changing the environment, the relationships, the access—is inseparable from the biological window the ceremony opens. Integration coaching at Transcend costs $150–$300 CAD per 60–90 minute session. A practical baseline is four sessions in the weeks immediately following ceremony. See the integration programme for what those sessions involve.
What this is not
Ibogaine is not a cure for stimulant addiction. It is not a cure for any addiction. The mechanism is real. The potential is genuine. The evidence base at clinical trial level for stimulant use disorder specifically does not yet exist.
The people who arrive at ibogaine ceremony with stimulant use disorder after having tried everything else—multiple treatment programmes, sustained abstinence attempts, approaches that held for months and then didn't—are not wrong to be here. Their scepticism about conventional treatment is evidence-based. What they should not arrive with is the expectation that ibogaine will resolve a condition that sustained itself over years through a single 12–24 hour experience, without integration work that follows.
The evidence for ibogaine and opioid dependence—the Stanford study, decades of clinical observation, replicated animal model data—is stronger than what currently exists for stimulant use disorder. Saying so is not a reason to avoid this path. It is a reason to approach it with accurate expectations. This is a treatment approach with a credible mechanism and genuine preliminary evidence, operating at a stage of research where outcomes data is emerging rather than established.
Providers who claim ibogaine is a proven cure for cocaine or methamphetamine addiction are not giving you accurate information. See ibogaine safety and what the screening protocol involves for what qualified providers are actually doing and why it matters.
Who cannot proceed
Absolute contraindications apply regardless of condition. They apply to someone with stimulant use disorder in the same way they apply to someone with opioid dependence or PTSD. The condition being addressed does not modify the cardiac risk or the drug interaction risk.
You cannot safely proceed if you have QT prolongation, significant cardiac arrhythmia, or a history of recent myocardial infarction. Ibogaine prolongs the QT interval throughout the 12–24 hour active experience—this is the primary mechanism through which documented ibogaine-related deaths have occurred, almost exclusively in the absence of pre-ceremony cardiac screening. A pre-ceremony EKG is required. This is not a formality. It is how the risk is identified before ceremony rather than during it.
Current SSRIs or SNRIs are an absolute contraindication. They are not a preference to work around. Administering ibogaine alongside an active SSRI creates the conditions for serotonin syndrome, which can be fatal. The medication must be fully tapered under physician supervision before a ceremony date is discussed. Fluoxetine requires 4–6 weeks of clearance after the final dose due to its long half-life. Lithium is an absolute contraindication without exception.
Someone with active psychosis or a schizophrenia-spectrum disorder cannot proceed. Someone with severe liver or kidney disease cannot proceed. Someone who is pregnant cannot proceed.
Someone in acute psychiatric crisis is not an appropriate candidate. Ibogaine amplifies what is present. Entering ceremony in a state of acute instability does not produce stability—it encounters instability directly.
The screening conversation that ends in a no is not a bureaucratic outcome. It is one of the most important things this work does. People in crisis who have found a thread of hope do not receive a no easily. Delivering it clearly, without softening it, is an act of care. See ibogaine contraindications for the full list and what each one means for eligibility.
Is this right for you?
If the medical screening does not disqualify you, if you can arrange protected recovery time—minimum 5–7 days—and if integration support is in place before ceremony rather than after, the next step is applying. The application is a conversation, not a commitment. Every application is read personally. Responses take 2–3 business days.